Close Menu

More articles about Research & Discovery

The company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.

The Singapore-based firm plans to use its single-cell RNA and protein assay to help optimize the production of CAR T cells and guide their use in patients.

A study of more than 10,000 women showed cancer predisposition genes confer similar risks of breast cancer in African-American women as in whites.

Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.

Tissue-agnostic drug development approaches have their own set of scientific and financial considerations, but some drugmakers are taking on those challenges.  

The actual match rate is significantly higher than the 10 percent rate the researchers anticipated they would see when the study began in 2017.

Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.

In work presented at the recent American Association for Cancer Research annual meeting, they found that T-cell cytokine production predicted patient response.

With genomic and proteomic profiles for more than 100 colon cancer cases, researchers identified drug targets, treatment resistance insights, potential cancer drivers, and more.

The analysis uncovered established subtypes and added new classifications, while also identifying a potential new treatment target.

Centene will contribute up to $100 million over 10 years to fund research into Alzheimer's disease, breast cancer, diabetes, and obesity at WashU.

Studies presented at the AACR meeting demonstrated how the registry can be used to evaluate how cancer patients with rare tumor markers respond to treatments.

Starting with samples from an 11-year-old boy with spitzoid melanoma, researchers identified recurrent MAP3K8 fusions that may respond to MEK inhibitors.

Researchers at UC Santa Cruz have found patterns in RNA sequencing data that have led to possible treatments for cancers with no actionable mutations.

The MammaSeq assay comprises 79 genes and 1,369 mutations in breast cancer that could be used as potential downstream therapeutic targets. 

The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.

Researchers were able to identify 40 tumor-specific antigens within two mouse cancer cell lines and seven human primary tumors using this approach.

Using a mouse model of immunotherapy resistant disease, the researchers found that this program could be targeted by an inhibitor to improve response.

A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.

The parties will use machine learning to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival.

Pages